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Background: Since healthcare-associated pneumonia (HCAP) is heterogeneous, clinical char-
acteristics and outcomes are different from region to region. There can also be differences
between HCAP patients hospitalized in secondary or tertiary hospitals. This study aimed to
evaluate the clinical characteristics of HCAP patients admitted into secondary community
hospitals.
Methods: This was a retrospective study conducted in patients with HCAP or community-
acquired pneumonia (CAP) hospitalized in two secondary hospitals betweenMarch 2009 and
January 2011.
Results: Of a total of 303 patients, 96 (31.7%) hadHCAP. 42 patients (43.7%) resided in anursing
home or long-term care facility, 36 (37.5%) were hospitalized in an acute care hospital for
≥ 2 days within 90 days, ten received outpatient intravenous therapy, and eight attended a
hospital clinic or dialysis center. HCAP patients were older. The rates of patients with CURB-
65 scores of 3 or more (22.9% vs. 9.1%; p=0.001) and PSI class IV or more (82.2% vs. 34.7%;
p<0.001) were higher in the HCAP group. Drug-resistant pathogens were more frequently
detected in the HCAP group (23.9% vs. 0.4%; p<0.001). However, Streptococcus pneumoniae
was the most common pathogen in both groups. The rates of antibiotic change, use of
inappropriate antibiotics, and failure of initial antibiotic therapy in the HCAP group were
signiﬁcantly higher. Although the overall survival rate of the HCAP group was signiﬁcantly
lower (82.3% vs. 96.8%; p<0.001), multivariate analyses failed to show that HCAP itself was
a prognostic factor for mortality (p = 0.826). Only PSI class IV or more was associated with
increased mortality (p = 0.005).
Conclusions: HCAP should be distinguished from CAP because of the different clinical fea-tures. However, the current deﬁnition of HCAP does not appear to be a prognostic for death.
f broIn addition, the use oS. pneumoniae was most fr
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Introduction
Pneumonia was traditionally classiﬁed as either community-
acquired pneumonia (CAP) or hospital-acquired pneumonia
(HAP), but in 2005 the American Thoracic Society (ATS) and
the Infectious Diseases Society of America (IDSA) introduced
the concept of healthcare-associated pneumonia (HCAP).1
ATS/IDSA guidelines state that patients with HCAP should
receive broad-spectrum empirical antimicrobial therapy
directed at multidrug-resistant (MDR) pathogens associated
with healthcare settings.1 This treatment strategy from the
ATS/IDSA guidelines is based on the epidemiology and clin-
ical outcomes of HCAP.2,3 That is, MDR bacteria such as
methicillin-resistant Staphylococcus aureus (MRSA) or Pseu-
domonas aeruginosa are isolated more frequently in patients
with HCAP and the mortality rates associated with HCAP are
signiﬁcantly higher than for CAP in some reports.2,4,5 There-
fore, treatment strategies based on this distinction between
HCAP and CAP are thought to be very important as guides to
the treatment of patients with pneumonia.
However, this concept has been controversial. The British
Thoracic Society (BTS) guidelines state that there is no dif-
ference in the distribution of causative pathogens between
patients with HCAP and elderly patients with CAP, although
its deﬁnitions of HCAP are somewhat different.6 A recent
prospective UK cohort study demonstrated that the increased
mortality in HCAP according to the 2005 ATS/IDSA deﬁnitions
was primarily related to underlying patient-related factors
rather than the presence of antibiotic-resistant pathogens.7
This study did not establish a clear indication to change cur-
rent prescribing practices in a UK cohort. A study from Europe
has shown that the microbiological and mortality data of
patients with nursing home-acquired pneumonia (the largest
subgroup of HCAP) are more similar to the data of those with
CAP.8 The reason for these varying results among studies
may be that HCAP itself is heterogeneous and the regions or
countrieswhere studieswere performedhad different compo-
sitions of HCAP subgroups and different healthcare systems.
In Korea, there are limited data and no guidelines focus-
ing on HCAP.9,10 Given that all of the studies were conducted
in tertiary referral hospitals with over 1,000 beds and included
relatively small numbers of patients residing innursinghomes
or long-termcare facilities (less than10%), the results are likely
to be biased towards more severe pneumonia or speciﬁc sub-
groups. Therefore, it is necessary to collect and evaluate data
regarding patients with HCAP admitted to secondary commu-
nity hospitals. This study aimed to clarify the differences in
the clinical characteristics of patientswithHCAP andCAPhos-
pitalized in secondary hospitals. Also, the clinical utility of
HCAP as a prognostic factor was investigated.
Material and methods
Study designThis study was performed at the Kyung Hee University Hospi-
tal at Gangdong (a 600-bed hospital in Seoul, South Korea) and
at the Jeju National University Hospital (a 540-bed hospital in
Jeju, South Korea). These hospitals are classiﬁed as secondary12;16(4):321–328
community hospitals according to the Korean healthcare sys-
tem.
Patients diagnosed with CAP (CAP group) or HCAP (HCAP
group) who were hospitalized in these hospitals between
March, 2009 and January, 2011 were evaluated. Clinical
characteristics, comorbidities, severity, identiﬁed pathogens,
antibiotic therapy and clinical outcomes were compared
between the two groups. The severity of pneumonia in each
group was determined using the CURB-65 (confusion, urea
nitrogen, respiratory rate, blood pressure, age≥ 65 years) score
and the PSI (Pnemonia Severity Index). The study protocol
was approved by the Ethical Review Committee of the two
institutions. Informed consent was waived because of the ret-
rospective nature of the study.
Categorization of pneumonia
Pneumonia was deﬁned as the presence of a new inﬁltrate on
the chest radiography plus at least one of the following: fever
(temperature ≥ 38.0◦ C) or hypothermia (temperature<35.0◦
C); new-onset cough with or without sputum production;
pleuritic chest pain; dyspnea; or altered breath sounds on
auscultation.11 Multi-lobar involvement was deﬁned as the
presence of pneumonic inﬁltrates in two or more lobes on
chest radiograph or computed tomography.
According to the 2005ATS/IDSAguidelines,1 the risk factors
for HCAP include hospitalization for two days or more in the
preceding 90 days, residence in a nursing home or extended
care facility, homewound care, chronic dialysiswithin 30 days,
and family member with MDR pathogens. In accordance with
the guidelines, the HCAP group of this study included patients
with any of the following: 1) residence in a nursing home or
long-term care facility; 2) recent history of hospitalization in
an acute care hospital for≥ 2 days in the past 90 days; 3) recent
outpatient intravenous therapy (such as antibiotic therapy or
chemotherapy) orwoundcarewithin thepast 30days; 4) atten-
dance at a hospital clinic or dialysis center in the last 30 days.1
CAP was deﬁned as a diagnosis of pneumonia in patients who
did not meet any of the criteria for HCAP.
Microbiology
Microorganisms in samples obtained from sputum, tracheal
aspirate, bronchial alveolar lavage ﬂuid, or blood were investi-
gated. Sputumwas deﬁned as adequatewhen>25 neutrophils
and<10 squamous epithelial cells seen under low-power ﬁeld.
For Mycoplasma pneumoniae or Chlamydia pneumoniae, serum
samples were evaluated. Serum samples in which particle
agglutination antibody titers were>320, or that were proven
to have a four-fold or greater increase of antibody titers in
paired sera, were regarded as positive. BinaxNOW® (Binax
Inc. – Maine, USA) was routinely used to detect urinary
antigens for Streptococcus pneumoniae. Seeplex® RV7 detec-
tion (Seegene, Inc. – Seoul, Korea) for respiratory viruses
including inﬂuenza A/B virus, parainﬂuenzavirus, adenovirus,
rhinovirus, metapneumovirus, respiratory syncytial virus and
®BinaxNOW Legionella Urinary Antigen Test (Binax, Inc. –
Maine, USA) for Legionella pneumophila serogroup 1 were
performed according to the clinical judgment of the attend-
ing physicians. The antibiotic sensitivity of all isolates was
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etermined using the disc diffusion method, and drug-
esistant pathogens were deﬁned as having resistance to two
r more different classes of antimicrobial drugs.
valuation for clinical outcomes
nappropriate antibiotic therapy was deﬁned if the empirical
ntibiotics were not effective against the identiﬁed pathogens
ased on in vitro susceptibility testing. Initial treatment fail-
re was deﬁned as death during initial treatment or change
f antibiotics from initial agents to another regimen after
8hours due to clinical instability. Intensive care unit (ICU)
dmission, need for mechanical ventilation, length of antibi-
tic therapy, length of hospital stay, and three- and 30-day
n-hospital mortality rates were also compared between
roups. The duration of overall survival (OS) was calculated
s the time interval between admission and death due to any
ause or last clinical contact.
tatistical analysis
ata are presented as number (%) or median (range) unless
therwise stated. Continuous variables were compared using
tudent’s t-test for normally distributed variables and the
ann-Whitney U test for non-normally distributed variables.
univariate analysis was carried out using the chi-square test
r Fisher’s exact test for categorical data. The duration of OS
as analyzedusing theKaplan-Meiermethod. Thedifferences
n OS were assessed using the log-rank test and multivari-
te Cox proportional hazards regression models were ﬁt to
ssess associations between patient characteristics and time
o death. p-values<0.05 were considered statistically signiﬁ-
ant. Analyses were performed using the Statistical Package
or the Social Sciences (SPSS) network version 18.0 (SPSS –
hicago, IL).
esults
linical characteristics
total of 303 patients (189 patients at Kyung Hee University
ospital at Gangdong and 114 patients at Jeju National Univer-
ity Hospital) were evaluated during the study period. There
ere 96 patients (31.7%) with HCAP and 207 (68.3%) with CAP.
he median age of the HCAP group was 76 years (interquartile
ange (IQR) 69-82) and that of CAP group was 65 years (IQR 51-
6), showing a statistically signiﬁcant difference between the
wo groups (p<0.001). In the HCAP group, 42 patients (43.7%)
esided in a nursing home or long-term care facility in the last
0 days, 36 patients (37.5%) were hospitalized in an acute care
ospital for ≥ 2 days in the last 90 days, 10 patients (10.4%)
eceived outpatient intravenous therapy within the past 30
ays, and 8 patients (8.3%) attended ahospital clinic or dialysis
enter in the last 30 days.
The baseline clinical features of the two groups are
resented in Table 1. Comorbidities, such as malignancy, car-
iovascular disease, renal disease, diabetes mellitus, chronic
ung disease, and central nervous system disorders were sig-
iﬁcantly more frequent in the HCAP group than in the CAP2;16(4):321–328 323
group. The rate of patients with two or more comorbidities
was higher in the HCAP group than in the CAP group (55.2% vs.
21.2%; p<0.001). The HCAP group had worse clinical parame-
ters such as confusion, respiratory failure, and septic shock at
onset than the CAP group. As a result, the rate of ICU admis-
sion and need for mechanical ventilation were signiﬁcantly
higher in the HCAP group. PSI and CURB-65 scores were also
higher in the HCAP group. The rates of patients with CURB-65
scores of 3 or more (22.9% vs. 9.1%; p=0.001) and PSI class IV
or more (82.2% vs. 34.7%; p<0.001) were higher in the HCAP
group.
A CT scan of the lungs was obtained within three days of
hospitalization for 176 patients (58.0%), including 54 (54.6%) in
the HCAP group and 122 (58.9%) in the CAP group. The rates of
multi-lobar involvement and pleural effusions between both
groups were not signiﬁcantly different (Table 2). The labo-
ratory proﬁles including hemoglobin, hematocrit, albumin,
blood urea nitrogen, and creatinine were worse in the HCAP
group. The HCAP group showed a trend for higher PCT level
compared with that of the CAP group (p=0.066).
Microbiological etiology
Table 3 shows the distribution of pathogens for HCAP and CAP.
An etiological diagnosis was possible for 55 patients (57.3%) in
theHCAP group and 84 patients (40.6%) in theCAP group. Strep-
tococcus pneumoniaewas thepathogen isolatedmost frequently
in both groups. However, the secondmost commonpathogens
were MRSA in the HCAP group and Mycoplasma pneumoniae in
the CAP group.
Drug-resistant pathogens were more frequently isolated in
the HCAP group (23.9% vs. 0.4%; p<0.001). MRSA, Pseudomonas
aeruginosaand Stenotrophomonasmaltophiliawere isolatedmore
frequently in the HCAP group than in the CAP group.
Clinical outcomes
Table 4 shows the initial antimicrobial regimens. More than
75% of all patients received combination therapy. Anti-
pseudomonal and/or anti-MRSA agents were used more
frequently in theHCAP group (66.6%vs. 3.8%, p<0.001; 4.1% vs.
0.4%, p=0.036, respectively). Although the duration of antibi-
otic administration was similar for both groups (14 vs. 14
days; p=0.607), the rates of antibiotic change (43.7% vs. 20.7%;
p<0.001), use of inappropriate antibiotics (23.9% vs. 5.7%;
p<0.001), and failure of initial antibiotic therapy (36.4% vs.
12.0%; p<0.001) were signiﬁcantly higher in the HCAP group
(Table 5). Although the in-hospital mortality rate at three days
was similar between the two groups, the HCAP group was hos-
pitalized longer (p=0.001) and showed a higher in-hospital
mortality rate at 30 days than the CAP group (p=0.001).
Survival
The three- and 30-day overall cumulative survival rates for all
patients with pneumonia were 97.6% and 90.7%, respectively
(Table 6). Notably, the OS rate of the HCAP group was signif-
icantly lower than that of the CAP group (OS rates: 82.3% vs.
96.8%, p<0.001, Fig. 1).
The prognostic factors associated with OS were age,
drug resistant pathogen, use of anti-pseudomonal and/or
324 braz j infect d i s . 2012;16(4):321–328
Table 1 – Baseline clinical features of patients with HCAP and CAP.
Characteristics HCAP (n=96) CAP (n=207) p
Age (years) 76 (69-82) 65 (51-76) < 0.001
Male 66 (68.7%) 131 (63.2%) 0.198
Smoking history 48 (50%) 98 (47.3%) 0.667
Comorbidity
Malignancy 20 (20.8%) 18 (8.6%) 0.003
Liver disease 7 (7.2%) 17 (8.2%) 0.782
Cardiovascular disease 17 (17.7%) 11 (5.3%) < 0.001
Renal disease 16 (16.6%) 11 (5.3%) < 0.001
Diabetes mellitus 33 (34.3%) 42 (20.2%) 0.008
Steroid medications 3 (3.1%) 3 (1.4%) 0.385
Chronic lung disease 30 (31.2%) 40 (19.3%) 0.022
Central nervous system disorders 50 (52.0%) 27 (13.0%) < 0.001
Autoimmune disease 3 (3.1%) 5 (2.4%) 0.711
Two or more comorbidities 53 (55.2%) 44 (21.2%) < 0.001
Use of antibiotics within the previous 90 days 37 (38.5%) 9 (4.3%) < 0.001
Clinical parameters
Confusion 34 (35.4%) 13 (6.2%) < 0.001
Respiratory failure* 44 (45.8%) 54 (26.0%) < 0.001
Septic shock at onset 23 (23.9%) 21 (10.1%) 0.001
ICU admission 26 (27.0%) 23 (11.1%) < 0.001
Need for mechanical ventilation 15 (15.6%) 13 (6.2%) 0.009
Indices for pneumonia severity
CURB-65 score 2 (1-3) 1 (0-2) < 0.001
CURB-65 score ≥ 3 22 (22.9%) 19 (9.1%) 0.001
PSI score 121 (95-148) 79 (55-107) < 0.001
PSI class IV and V 79 (82.2%) 72 (34.7%) < 0.001
pneu
s or wData are presented as number (%).
HCAP, healthcare-associated pneumonia; CAP, community-acquired
∗ Respiratory failure was deﬁned when the PaO2 was 60mmHg or les
anti-MRSA agents, CURB-65 score, PSI class, and designation
of HCAP in univariate analysis. However, a multivari-
ate Cox proportional hazards model for time to death
showed that only PSI class IV or more was indepen-
dently associated with increased mortality in patients
Table 2 – Radiological and laboratory ﬁndings of patients with H
Characteristics HCAP (n=96)
Radiological ﬁndings
Multi-lobar involvement* 54 (56.2%)
Pleural effusion 25 (26.0%)
Laboratory proﬁles
WBC 10400 (7075-15225)
Hemoglobin (/L) 10.7 (9.2-12.0)
Hematocrit (%) 31.5 (27.6-35.3)
Platelet (x 103/L) 207 (159-287)
Glucose (mg/dL) 130 (107-177)
Albumin (g/dL) 3.3 (2.9-3.8)
Blood urea nitrogen (mg/dL) 22 (14-33)
Creatinine (mg/dL) 1.2 (0.9-1.7)
Sodium (mEq/L) 137 (133-139)
C-reactive protein (mg/dL) 13.0 (4.2-21.9)
Procalcitonin (ng/dL) 0.63 (0.12-4.42)
Data are presented as median (interquatile range) or number (%).
HCAP, healthcare-associated pneumonia; CAP, community-acquired pneu
∗ Multi-lobar involvement was deﬁned as the presence of pneumonic i
tomography.monia; ICU, intensive care unit.
hen the PaO2/FiO2 ratio was 300mmHg or less.
diagnosed with pneumonia (OR: 9.182, 95% CI: 1.951-43.219,
p=0.005) (Table 7). Otherwise, male gender, age, polymicro-
bial pathogens, drug-resistant pathogens, CURB-65 score ≥
3, and HCAP diagnosis were not signiﬁcantly associated with
survival.
CAP and CAP.
CAP (n=207) p
96 (46.3%) 0.110
50 (24.1%) 0.723
10800 (7100-13800) 0.693
12.5 (11.4-14.0) 0.001
36.5 (33.4-40.8) 0.001
215.0 (180-287) 0.255
121 (105-153) 0.133
3.9 (3.6-4.2) 0.001
15 (11-20) 0.001
1.0 (0.9-1.2) 0.009
137 (135-139) 0.367
10.7 (5.7-18.9) 0.402
0.13 (0.05-1.97) 0.066
monia; WBC, white blood cell.
nﬁltrates in two or more lobes on chest radiograph or computed
braz j infect d i s . 2012;16(4):321–328 325
Table 3 – Microorganisms identiﬁed in patients with HCAP and CAP.
Microorganisms HCAP (n=96) CAP (n=207) p
Gram-positive bacteriae
Streptococcus pneumoniae 24 (25.0%) 41 (19.8%) 0.306
Other streptococci 1 (1.0%) 4 (1.9%) 1.000
Staphylococcus aureus
MSSA 1 (1.0%) 3 (1.4%) 1.000
MRSA 8 (8.3%) 2 (0.9%) 0.002
Coagulase-negative staphylococci species 0 (0%) 1 (0.4%) 1.000
Gram-negative bacteria
Mycoplasma pneumoniae 4 (4.1%) 18 (8.6%) 0.158
Klebsilla pneumoniae 5 (5.2%) 3 (1.4%) 0.115
Pseudomonas aeruginosa 4 (4.1%) 1 (0.4%) 0.036
Stenotrophomonas maltophilia 3 (3.1%) 0 (0%) 0.031
Escherichia coli 2 (2.0%) 0 (0%) 0.100
Enterobacter species 2 (2.0%) 0 (0%) 0.100
Acinetobacter species 2 (2.0%) 0 (0%) 0.100
Moraxella catarrhalis 2 (2.0%) 0 (0%) 0.100
Haemophilus inﬂuenza 0 (0%) 3 (1.4%) 0.554
Virus
Inﬂuenza virus 1 (1.0%) 5 (0.4%) 0.669
Parainﬂuenza virus 0 (0%) 1 (0.4%) 1.000
Adenovirus 0 (0%) 1 (0.4%) 1.000
Unknown 41 (42.7%) 123 (59.4%) 0.009
Polymicrobial pathogens 7 (7.2%) 9 (4.3%) 0.286
Drug resistant pathogens* 23 (23.9%) 1 (0.4%) < 0.001
Data are presented as number (%).
HCAP, healthcare-associated pneumonia; CAP, community-acquired pneumonia; MSSA, methicillin-sensitive Staphylococcus aureus; MRSA,
or m
D
D
Amethicillin-resistant Staphylococcus aureus.
∗ Drug resistant pathogens were deﬁned as having resistance to two
iscussionata published shortly after the establishment of the 2005
TS/IDSA guidelines demonstrated that the spectrum of
Table 4 – Initial antibiotic treatment.
Treatment regimens HCAP (n=96)
Monotherapy 19 (19.7%)
Combination therapy 77 (80.2%)
Use of anti-pseudomonal agent 64 (66.6%)
Use of anti-MRSA agent 4 (4.1%)
Data are presented as number (%).
HCAP, healthcare-associated pneumonia; CAP, community-acquired pneu
Table 5 – Clinical outcomes of patients with HCAP and CAP.
Clinical outcomes HCAP (n=96)
Duration of antibiotic therapy (days) 14 (11-18)
Change of antibiotics 42 (43.7%)
Use of inappropriate antibiotics 23 (23.9%)
Failure of initial antibiotic therapy 35 (36.4%)
Length of hospital stay (days) 12 (8-19)
3-day in-hospital mortality rate 3 (3.1%)
30-day in-hospital mortality rate 17 (17.7%)
Data are presented as number (%).
HCAP, healthcare-associated pneumonia; CAP, community-acquired pneuore different classes of antimicrobial drugs.
microorganisms found in HCAP was more similar to HAP than
2CAP. In particular, data from the United States has contin-
ued to conﬁrm this ﬁnding. Thereafter, several major studies
have investigated differences in the clinical characteristics of
patients with HCAP and CAP.5,7,9,12–14 The ﬁndings of some
CAP (n=207) p
49 (23.6%) 0.451
158 (76.3%) 0.451
8 (3.8%) < 0.001
1 (0.4%) 0.036
monia; MRSA, methicillin-resistant Staphylococcus aureus.
CAP (n=207) p
14 (11-17) 0.607
43 (20.7%) < 0.001
12 (5.7%) < 0.001
25 (12.0%) < 0.001
8 (5-11) 0.001
4 (1.9%) 0.683
11 (5.3%) 0.001
monia.
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Table 6 – Univariate analysis for overall survival.
No Overall cumulative survival
Mean survival
(days)
3-day survival 30-day survival p
Total group 303 462 97.6% 90.7%
Gender 0.525
Male 196 476 97.4% 90.3%
Female 107 436 98.1% 91.5%
Age <0.001
≥ 65 years 192 408 96.8% 86.4%
<65 years 111 555 99.0% 98.1%
Polymicrobial pathogens 1.000
Yes 16 515 100% 100%
No 287 459 97.5% 90.2%
Drug resistant pathogens 0.103
Yes 26 428 100% 84.6%
No 277 465 97.4% 91.3%
Use of anti-pseudomonal agent <0.001
Yes 72 208 94.4% 77.7%
No 231 504 98.7% 93.0%
Use of anti-MRSA agent 0.045
Yes 5 160 100% 60%
No 298 438 97.6% 91.2%
CURB-65 score <0.001
≥ 3 41 271 98.8% 63.4%
<3 262 492 98.4% 95.0%
PSI class <0.001
≥ IV 151 361 95.3% 82.1%
< IV 152 563 100% 99.3%
Pneumonia type <0.001
HCAP 96 332 96.8% 82.3%
CAP 207 552 98.0% 94.7%
pneuHCAP, healthcare-associated pneumonia; CAP, community-acquired
recent studieshave beendifferent from those of previous stud-
ies. Therefore, some authors or experts are now questioning
whether the ATS/IDSA deﬁnition of HCAP should be reﬁned or
abandoned.15 The differences in the results of these studies
can be explained by differences in the subgroups of patients
with HCAP and in the healthcare systems of each country.
As of 2011, a large scale, multi-center cohort study in Korea
hadnot been performed to evaluate the clinical characteristics
Table 7 – Cox’s proportional hazard model for mortality in patie
Variables Odds ratio
Male 0.911
Age≥ 65 years 1.956
Polymicrobial pathogens 0.421
Drug resistant pathogens 1.029
Use of anti-pseudomonal agent 1.597
Use of anti-MRSA agent 1.460
CURB-65 score ≥ 3 1.926
PSI class IV and V 9.182
HCAP 0.906
HCAP, healthcare-associated pneumonia; CAP, community-acquired pneumonia; MRSA, methicillin-resistant Staphylococcus aureus.
of HCAP. Two single-center studies were conducted in tertiary
referral centers that have over 1,500 beds.9,16 These stud-
ies included a high proportion of patients who had received
chemotherapy or who had a recent hospitalization, while
the rate of patients residing in nursing homes was low. This
patient distribution is a result of the distinct features of ter-
tiary referral hospitals according to the healthcare system of
Korea. Thus, the results of these studies cannot explain the
nts with pneumonia.
95% CI p
0.435-1.908 0.805
0.559-6.851 0.294
0.054-3.255 0.407
0.375-2.826 0.956
0.669-3.816 0.292
0.308-6.917 0.634
0.933-3.973 0.076
1.951-43.219 0.005
0.377-2.179 0.826
monia; MRSA, methicillin-resistant Staphylococcus aureus.
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Fig. 1 – Overall survival of healthcare-associated
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(eneral characteristics of patientswithHCAP inKorea because
hey are likely to be biased toward more severe pneumonia or
peciﬁc subgroups.
The average age of the population in Korea as well as
n Western countries is increasing. The population above 65
ears of age in Korea will be as high as 14.3% in 2019.17 This
emographic feature will lead to increased numbers of the
lderly residing in long-term care facilities such as nursing
omes. The proportion of elderly patients with pneumonia
ontinues to increase. Most of the elderly patients with pneu-
onia, either CAP or HCAP, will be hospitalized in secondary
ommunity hospitals because there aremanymore secondary
ospitals in Korea than tertiary referral hospitals. The clini-
al features of patients admitted to secondary hospitals may
e different from those admitted to tertiary referral hospitals.
herefore, it is important to analyze the clinical features of
atients with HCAP admitted to secondary hospitals in given
region or country.
This is the ﬁrst study that was performed at two secondary
ospitals in Korea. The present study showed that approxi-
ately 30% of the patients with pneumonia hospitalized in
secondary hospital in Korea were diagnosed with HCAP. In
erms of subgroups of HCAP, 43.7% of the patients in this study
esided in a nursing homeor long-termcare facility,while only
0.4% had received outpatient IV therapy such as chemother-
py. This ﬁnding has epidemiological signiﬁcance because the
omposition of the subgroups in this study was different from
hose of previous Korean studies.9,16 A possible reason for this
nding is that HCAP itself is heterogeneous, and subgroups of
CAP can have individual clinical features.
In terms of microbiology, the most commonly identiﬁed
icroorganism in HCAP was Streptococcus pneumoniae, the
ost common bacteria of CAP. This result was also different
rom the results of previous Korean studies.9,16 In contrast,
RSA and Gram-negative bacteriae such as P. aeruginosa were
solated more frequently in the HCAP group. After the estab-
ishment of the 2005 ATS/IDSA guidelines for HCAP in Korea,
any Korean physicians have included anti-pseudomonal
nd/or anti-MRSAagents into initial regimens to treat patients
ith HCAP. In the present study, anti-pseudomonal agents
ere administered to 66.6% of the patients in the HCAP
roup, compared with 3.8% of the patients in the CAP group
p<0.001). These results provide meaningful information.2;16(4):321–328 327
First, since there are microbiological differences between
HCAP andCAP, clinicians caring for patientswithHCAP should
always consider drug resistant pathogens. Second, empirical
regimens to cover resistant pathogens such as P. aeruginosa
can be unnecessary inmany patientswithHCAP admitted into
secondary hospitals. Although P. aeruginosa was isolated more
frequently in HCAP group, its rate was low (4.1%) in our study.
However, clinicians prescribed anti-pseudomonal agents to
ﬁght this organism in 66.6% of patients with HCAP. Predictive
rules thought to accurately identify HCAP patients who are
likely to have or not have drug-resistant pathogens should be
developed. Further analyses of the subgroups of HCAP may be
necessary for this purpose.
In addition to drug resistant pathogens, higher rates of
inappropriate antibiotics, of failure of initial antibiotic ther-
apy, and of 30-day mortality were observed in the HCAP group.
However, multivariate analyses showed that HCAP itself was
not a risk factor for mortality, and that severity indices of
pneumonia such as the PSI were much more predictive of
mortality. This ﬁnding underlies the fact that the current
HCAP deﬁnition as a category of pneumonia, as some authors
emphasize, may not be useful. However, this result may be
due to the composition of the HCAP subgroups. The possibil-
ity that a speciﬁc subgroup would be a risk factor for death
cannot be ruled out.
The present study has several limitations. First, since this
study had a relatively small number of patients with HCAP
and was performed retrospectively at two secondary Korean
hospitals, it should be interpreted with caution, and its ﬁnd-
ings cannot be considered to be consistent with those of other
secondary hospitals. A nationwide cohort study should be per-
formed to overcome these limitations. Second, the ATS/IDSA
2005 guidelines recommend semi-quantitative or quantitative
culture in patients with HCAP to identify causative microor-
ganisms. However, semi-quantitative or quantitative cultures
were not performed for most of the patients. Therefore, the
microorganisms identiﬁed could be oropharyngeal colonizers
and may not have been the deﬁnite causes of pneumonia,
since sputum culture may not always distinguish between
colonization and true infection despite adequate sputum col-
lection. In spite of the limitations described above, the present
study showed meaningful data regarding patients with HCAP
hospitalized in secondary hospitals in Korea.
In summary, the clinical characteristics of patients with
HCAP admitted into secondary hospitals in Korea are differ-
ent from thosewith CAP. However, the currentHCAPdeﬁnition
seems not to be associated with in-hospital mortality. In addi-
tion, because drug-sensitive S. pneumonia was identiﬁed most
frequently in patients with HCAP, the use of antibiotics with
extensive spectrum as recommended by the ATS/IDSA guide-
lines should be reassessed in the healthcare system of Korea,
although patients with HCAP were more likely to receive inap-
propriate initial antibiotics. Also, a nationwide cohort study is
needed to establish proper guidelines regarding HCAP.Conﬂict of interest
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